BioSpace News Archive

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021.

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, today announced it has received Human Research Ethics Committee (HREC) approval to start its Phase I intravenous (IV) clinical trial evaluating the safety and pharmacokinetics of its lead compound, RECCE® 327 (R327).

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107’s potential pro-motoric impact in Parkinson’s disease patients.

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alvelestat for the treatment of alpha-1 antitrypsin deficiency (AATD).

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company has entered into a strategic partnership with Sinopharm Group Co. Ltd. (“Sinopharm”) to strengthen its commercial capabilities and accelerate its commercialization transformation.

PTC Therapeutics, Inc. announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET.

Mozart Therapeutics, Inc. today announced a $55 Million Series A Financing led by seed and Series A investor ARCH Venture Partners

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

SymBiosis Capital Management, LLC (“SymBiosis”) today announced its launch as a newly independent venture capital firm focused on advancing biotherapeutics innovations.

OpRegen ® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.